Dexcom and Abbott Await Medicare Coverage Expansion for Continuous Glucose Monitors
Diabetes technology companies Dexcom (DXCM) and Abbott (ABT) are closely monitoring the potential expansion of Medicare coverage to include continuous glucose monitors (CGMs) for people with Type 2 diabetes who do not take insulin. Currently, CGM coverage is limited to those using insulin or experiencing problematic low blood sugar episodes. Dexcom CEO Jake Leach expects a decision from the Centers for Medicare and Medicaid Services by year-end, potentially leading to expanded access in mid-2027. Dexcom estimates that about 12.5 million eligible individuals could benefit if coverage is extended. The company recently presented clinical trial results showing improved glucose control among CGM users. Abbott's CEO Robert Ford also anticipates a significant market opportunity, estimating the expansion could make an additional 10 million Medicare recipients eligible for CGMs and boost commercial insurance adoption.
Topics: diabetes healthcare_policy medical_devices